Just over four months after our first close, we are happy to announce ACP Credit’s first investment.
We partnered with a Polish biotech company, Biomed Lublin S.A., established back in 1944, specialising, among others, in tuberculosis (BCG) vaccine and BCG-derivative bladder tumour products.
ACP Credit’s loan of EUR 9 million, expected to increase to EUR 13 million, will part-fund (together with equity and EU grants) a capacity expansion programme, which will allow Biomed to address the unmet demand in the bladder tumour treatment, which has been the principal way in which this type of cancer has been treated since 1977